Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth using 1mg finasteride every other day and 1ml topical minoxidil daily, with initial shedding but improvement by three months. Microneedling was also used, with adjustments to frequency and needle length for better results.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The user is considering adding microneedling to their current hair loss regimen, which includes 1mg finasteride daily, 1.25mg oral minoxidil twice daily, and Nizoral once a week. Opinions on microneedling's effectiveness vary, but some suggest it could enhance results.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

The user is using finasteride 1mg every other day and seeks a topical solution excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.

Finasteride's impact on fertility is discussed, with users sharing experiences of conceiving while on the medication. Concerns about long-term safety are also mentioned.

The user has been using 1.25mg of finasteride daily for one year to address hair loss. Progress pictures are included to show the results.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation discusses the potential use of HMI 115 for hair loss and whether it could replace or be used alongside finasteride, minoxidil, and RU58841. The user is experiencing scalp inflammation and continued hair shedding despite using finasteride for 8 years.

A user's progress in treating their hair loss with Finasteride, Minoxidil and Dermarolling; they discussed details of their routine and others congratulated them on their success.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

The user experienced significant hair growth using topical finasteride and minoxidil but noticed nipple changes, suggesting early gynecomastia. They plan to stop the treatment and consider blood work to check hormonal balance.

Microneedling is discussed as a favorable hair loss treatment, with no consensus on whether to glide or remove the device between areas. Scalp irritation varies by individual, and some users report no need for gel during the process.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

A 32-year-old is seeing positive hair regrowth after nearly three months using finasteride, oral and liquid minoxidil, and microneedling, and plans to add RU58841. They are considering switching to dutasteride and possibly a hair transplant in the future.

A 21-year-old is using finasteride and previously used minoxidil for hairline concerns, considering a hair transplant despite no visible balding. They are advised to continue finasteride as a preventive measure.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

The user shared progress pictures showing hair improvement after using 1mg finasteride daily and 5% minoxidil spray once a day for six months. Other users suggested adding microneedling to enhance results and discussed side effects and product recommendations.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The user shared progress pictures showing significant hair regrowth after 6 months of using 1mg finasteride and 2.5mg minoxidil, with no side effects reported. They added Nizoral to their routine to address an itchy scalp.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

Using alfatradiol can cause nausea and headaches. Users discuss these side effects and seek advice.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.